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Abstract: Background. Individual variations in gastric cancer risk have been associated in the last decade with specific 
variant alleles of different genes that are present in a significant proportion of the population. Polymorphisms may modify 
the effects of environmental exposures, and these gene-environment interactions could partly explain the high variation of 
gastric cancer incidence around the world. The aim of this report is to carry out a systematic review of the published meta-
analyses of studies investigating the association between gene polymorphisms and gastric cancer risk, and describe their 
impact at population level. Priorities on the design of further primary studies are then provided.  
Methods. A structured bibliographic search on Medline and EMBASE databases has been performed to identify meta-
analyses on genetic susceptibility to gastric cancer, without restriction criteria. We report the main results of the meta-
analyses and we describe the subgroup analyses performed, focusing on the detection of statistical heterogeneity. We in-
vestigated publication bias by pooling the primary studies included in the meta-analyses, and we computed the population 
attributable risk (PAR) for each polymorphism. 
Results. Twelve meta-analyses and one pooled-analysis of community based genetic association studies were included, 
focusing on nine genes involved in inflammation (IL-1, IL-1RN, IL-8), detoxification of carcinogens (GSTs, CYP2E1), 
folate metabolism (MTHFR), intercellular adhesion (E-cadherin) and cell cycle regulation (p53). According to their ran-
dom-Odds Ratios, individuals carrying one of the IL-1RN *2, IL-1 -511T variant alleles or homozygotes for MTHFR 
677T are significantly at higher risk of gastric cancer than those with the wild type homozygote genotypes, showing high 
PARs. The main sources of heterogeneity in the meta-analyses were ethnicity, quality of the primary study, and selected 
environmental co-exposures. Effect modification by Helicobacter pylori infection for subjects carrying the unfavourable 
variant of IL-1 polymorphisms and by low folate intake for individuals homozygotes for MTHFR 677T allele has been re-
ported, while genes involved in the detoxification of carcinogens show synergistic interactions. Publication bias was ob-
served (Egger test, p = 0.03). 
Discussion. The published meta-analyses included in our systematic review focused on polymorphisms having a small ef-
fect in increasing gastric cancer risk per se. Nevertheless, the risk increase by interacting with environmental exposures 
and in combination with additional unfavourable polymorphisms. Unfortunately meta-analyses are underpowered for 
many subgroup analyses, so additional primary studies performed on larger population and collecting data on environ-
mental and genetic co-exposures are demanded.  
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INTRODUCTION 
  Gastric cancer is the second leading cause of death from 
cancer worldwide, although mortality rates have been de-
creasing since several decades due to decreased incidence 
and improvement of survival [1]. Gastric carcinogenesis is a 
multistep and multifactorial process as a result of a complex 
interaction between environmental and genetic factors. 
Among the former, Helicobacter pylori infection, tobacco 
smoking, low fruit and vegetable intake, high meat and salt 
intake, and the lack of food refrigeration have been shown to  
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be the major non-genetic determinants [2]. On the other side, 
a positive family history for gastric cancer is reported to be 
associated with the highest risk of gastric cancer [3]. In fam-
ily studies, first degree relatives of patients with gastric can-
cer have two-to-three fold increase risk of gastric cancer not 
explained by familial clustering of Helicobacter pylori infec-
tion [4]. It has also been demonstrated that different genetic 
pathways lead to diffuse and intestinal subtypes of gastric 
cancer [5], confirming the functional role of genetic factors 
on cancer susceptibility. Beside the familial clustering, the 
individual genetic susceptibility to gastric cancer probably 
involves many genes [6], although their effects may only be 
small. However, the combination of even a few small effects 
could account for a sizeable population attributable fraction 
of gastric cancer. In the last decade the association between 362    Current Genomics, 2008, Vol. 9, No. 6  Gianfagna et al. 
polymorphisms and gastric cancer has been investigated 
within community-based genetic association studies, aiming 
also to explore gene-gene and gene-environment interaction. 
Identifying the inherited genetic variants that modify the 
effect of well known nocive environmental exposures in gas-
tric cancer risk could eventually lead to more effective pri-
mary intervention. This, however, is still an open issue [7].  
  According to the role of the genes whose polymorphisms 
have been studied in association with gastric cancer, we can 
grouped them into the following categories: genes involved 
in the protection of gastric mucosa against damaging agents, 
in inflammatory response, in detoxification of carcinogens, 
in synthesis and repair of DNA, in regulation of gene expres-
sion, in cell adhesion and in cell cycle [4,8]. Since the effect 
of each individual polymorphism could be small, association 
studies in genetic epidemiology benefit from large sample 
sizes. The majority of the published studies, however, are 
underpowered to detect a robust association. With the grow-
ing number of published papers, some authors attempted to 
quantitatively summarize the results of each individual 
polymorphism in association with gastric cancer by using the 
meta-analytical approach. This allows for enhancing the 
power of the association analysis by pooling data, and to 
identify potential causes of discrepancies among studies by 
performing sensitivity analyses while investigating data het-
erogeneity. Currently meta-analysis is the most cited study 
design in health sciences [9] and is widely accepted as the 
highest level of evidence in medicine. Initially adopted to 
summarize the results from clinical trials, meta-analyses 
were then widely applied to observational studies, including 
genetic epidemiology studies. The reliability of meta-
analysis results, however, depends mainly on a rigorous 
methodology, on the quality of primary studies included and 
the availability for individual data collected from primary 
studies [10,11]. The latter aspect would allow to perform 
subgroup meta-analysis to explore gene-gene and gene-
environment interaction, both suffering from a low power in 
individual studies.  
  This systematic review of the published meta-analyses of 
observational studies investigating the relationship between 
gene polymorphisms and gastric cancer aims to: i) system-
atically review the role and the biological plausibility of each 
polymorphism in association with gastric cancer; ii) evaluate 
the attributable proportion of gastric cancer related to each 
polymorphismin the population ; iii) investigate the strengths 
and limitations of the published meta-analyses in order to 
suggest priorities for primary studies. 
METHODS 
  Identification of the meta-analyses of community-based 
association studies on polymorphisms and gastric cancer was 
carried out through a search of Medline and Embase, up to 
March 2008. The search strategy was carried out by combin-
ing the following terms: gastric, cancer, meta-analysis (with 
both synonymous and plural forms), as well as the truncated 
words ‘genetic*’, ‘allel*’ or ‘polymorphi*’, without any 
restriction on language. The references of retrieved papers 
was also examined to search for additional meta-analyses. 
The identified studies were screened by two authors inde-
pendently (FG and EDF). The following topics were re-
ported: biological role of each genetic polymorphism, gene 
expression at tissutal level, frequency of variant allele carri-
ers in the population, overall results of the most appropriate 
observed genetic model from the meta-analysis reported as 
random effect Odds Ratio (OR) for gastric cancer and 95% 
confidence interval (CI), along with the p value for hetero-
geneity when available. Random effect model was used 
assuming heterogeneity between studies. Subgroup meta-
analyses were reported when authors had actually performed, 
and observed changes in the statistical heterogeneity were 
discussed.  
  The publication bias of the individual studies on gene 
polymorphisms and risk of gastric cancer was investigated 
by visual inspection of the funnel plot [12]. In order to have 
comparable data, the funnel plot was constructed by dividing 
the ORs of gastric cancer due to the unfavourable genotype 
from each individual study by the OR resulting from the cor-
responding published meta-analysis. The presence of publi-
cation bias was tested also with Begg and Mazumdar ad-
justed rank correlation test [13] and the Egger regression 
asymmetry test [14]. Lastly, we stratified the funnel plot 
according to the period of publication of the primary studies 
included in the meta-analysis. Accordingly, the first period 
of publication is defined as the period including primary 
studies published on the left fifty percentile of the time pe-
riod spanning from the first paper published on that poly-
morphism to the last published one.  
  Furthermore, in order to have a comprehensive view of 
the impact of each polymorphism on gastric cancer at popu-
lation level, we computed their population attributable risk 
(PAR) among Caucasians and Asians. PAR for each poly-
morphism was computed as (OR-1)/OR * (number of ex-
posed cases/total number of cases)] [15], using the ORs 
stratified for ethnicity and the pooled proportion of exposed 
cases for each ethnic subgroup both derived from the meta-
analyses including the largest number of individuals. The 
95% CI was computed as suggested by Natarajan et al. [16]. 
Statistical analyses were carried out using the STATA soft-
ware package v.9.2 (Stata Corporation, College Station, 
Texas). 
POLYMORPHISMS AND GASTRIC CANCER RISK 
  Twelve meta-analyses and 1 meta- and pooled-analysis 
published since 2005 to 2008 were retrieved, focusing on 12 
polymorphisms of 9 genes involved in inflammation (IL-1A, 
IL-1B, IL-1RN, IL-8), detoxification of carcinogens (GSTM1, 
GSTT1, CYP2E1), folate metabolism (MTHFR), intercellular 
adhesion (E-cadherin) and cell cycle regulation (p53) [17-
29]. The main characteristics of each meta-analysis are re-
ported in Fig. (1). The number of primary studies included in 
the meta-analyses ranged from 4 to 29, with a number of 
subjects included spanning from 2,500 to 10,000. Results of 
the meta-analysis including the largest number of individuals 
for each polymorphism are shown in Table 1. The results of 
all the included meta-analyses are reported in the following 
paragraphs. 
Interleukin-1  
  Several genes involved in the inflammatory pathway 
have been investigated in relation with gastric cancer [8,30], A Systematic Review of Meta-Analyses  Current Genomics, 2008, Vol. 9, No. 6    363 
in view of the immune response modulation in chronic gas-
tritis, being one of the early phases in the development of 
intestinal gastric cancer type [31]. The interleukin (IL) genes 
are the most widely studied, especially the IL-1A, IL-1B and 
IL-1RN, contained in the IL-1 cluster, which encode for the 
proinflammatory cytokines IL-1 and IL-1 and their en-
dogenous receptor antagonist IL-1RA, respectively [32].  
 IL-1 enhances the immune response with consequent 
free radical production, which may lead to lipid peroxidation 
and DNA damage, usually neutralized by efficient antioxi-
dant defence system [33]. Furthermore, IL-1 inhibits gastric 
acid secretion, which could lead to increased production of 
gastrin, a cell growth factor involved in many processes, 
including neoplastic transformation [34]. Helicobacter pylori 
infection induces IL-1 production [35], and consequent 
hypochlorydria favours further colonization by pH-sensitive 
Helicobacter pylori, leading to the development of atrophic 
gastritis and adenocarcinoma [36]. It has been demonstrated 
that IL-1 overexpression can directly induce gastric atrophy 
and dysplasia both in presence or absence of Helicobacter 
pylori infection [37]. Three polymorphisms of the IL1-B 
gene have been observed to increase IL-1 expression: CT 
transitions at both positions -511 and +3954 base pairs, and 
TC at -31 base pairs from the transcriptional start. IL-1B  
-31C/T is a TATA-box polymorphism which was observed 
to affect DNA-protein interactions [38]. IL-1B -511T and IL-
1B -31C are in near-complete linkage disequilibrium and the 
frequency of mutant alleles is 33% in Caucasians and about 
50% in Asians. IL-1B +3954T frequency distribution ranges 
from 5-10% in Asiatic and Hispanic populations to 23% in 
Caucasians [22].  
  Interleukin-1 receptor antagonist (IL-1RA) is an impor-
tant anti-inflammatory cytokine that can prevent the binding 
of IL-1 to its cell-surface receptors, thus modulating its ef-
fects. A variable number tandem repeat (VNTR) polymor-
phism has been detected within intron 2 of the human inter-
leukin-1 receptor antagonist gene (IL-1RN), consisting of 
repeats of an 86-bp sequence. Five allelic variants have been 
identified wherein the number of repeats varies from two (*2 
allele) to six (long alleles, 3-6 repeats) [39]. Carriers of IL-
1RN  *2 variant allele produce high levels of IL-1 
[36,40,41]. The IL-1RN VNTR region has 3 protein binding 
sites, suggesting a possible functional significance, although 
the mechanism underlying the association between the IL-
1RN *2 allele and enhanced IL-1 expression is currently 
unknown. The frequency distribution of the IL1-RN *2 car-
rier status ranges from 6% in Asians to 27-30% among Cau-
casians and Hispanics [22].  
  The association between genetic variations within the IL-
1 gene cluster and gastric cancer was firstly investigated by 
El-Omar  et al. in 2000 [38]. During 2006 three meta-
analyses on IL-1 gene cluster and gastric cancer were pub-
lished almost at the same time. The largest one from Wang et 
al. included 39 primary studies, totalling for 7000 gastric 
cancer cases and 8500 controls [23], while 35 [21] and 25 
primary studies [22] were included in remaining two studies 
(Fig. 1). Results are discussed below, while results of the 
largest meta-analysis are reported in Table 1.  
IL-1B -511T 
  In the meta-analysis of Camargo et al. [22], which in-














°Data from pooled-analysis; §Odds Ratio, Confidence Interval; for the main effect the reference is the homozygous wild-type genotype. 
Fig. (1). Description of the meta-analyses included in the systematic review. 364    Current Genomics, 2008, Vol. 9, No. 6  Gianfagna et al. 
propriate for -511T allele, according to the ORs derived by 
comparing the three genotypes [42]. Individuals carrying   
-511T variant allele have a borderline significantly increased 
risk of gastric cancer (OR = 1.21, 95%CI: 1.00-1.47) com-
pared with CC homozygotes, however high level of hetero-
geneity resulted (p for heterogeneity <0.001). Subgroup 
analyses stratified by ethnicity, site, histological subtype, age 
and sex matching, quality of included studies and sample 
size, were carried out to explore potential sources of hetero-
geneity. High quality studies reported a meta-OR of 1.77 
(95%CI: 1.49-2.09, p for heterogeneity = 0.81), while pool-
ing only large sample sizes ( >400 subjects) studies an OR of 
1.86 (95%CI: 1.50-2.31; p for heterogeneity = 0.72). Lastly, 
an OR of 1.66, (95%CI: 1.29-2.13; p for heterogeneity = 
0.71) resulted from only non-cardia gastric cancer. Interest-
ingly the increased risk for gastric cancer was confirmed in 
Caucasians, particularly among those with the intestinal sub-
type, while no association was found among Asians.  
Table 1.  Results of the Most Appropriate Genetic Model from the Meta-Analysis Including the Largest Number of Primary Stud-
ies for Each Genetic Variant 
IL-1B -511T Carriers 
[23]
 
IL-1B -31C Carriers 
[23] 
IL-1B +3954T Carriers 
[23] 




p53 codon 72 Arg/Arg 
[20] 
 
^p het.  OR  95% CI  p het.  OR  95% CI  p het.  OR  95% CI  p het.  OR  95% CI  p het.  OR  95% CI  p het.  OR  95% CI 
Overall <0.01  1.26  1.03-1.55  <0.01  1.00  0.82-1.22  <0.01  1.37  0.94-2.00  <0.01  1.20  1.01-1.41  0.03 1.12  0.90-1.40  0.04  0.96  0.79-1.16 
Caucasian   1.42  0.97-2.06   1.10  0.81-1.50   1.15  0.84-1.57   1.30  1.09-1.54         1.32  0.89-1.97 
Asian   1.16  0.92-1.46   0.92  0.71-1.18   1.73  0.59-5.05   1.09  0.78-1.52         0.84  0.72-0.99 
High quality   1.07  0.80-1.42   0.98  0.73-1.30   1.67  0.84-3.32   1.13  0.86-1.49           
Population controls   1.13  0.94-1.36   0.96  0.78-1.19   1.15  0.97-1.36   1.21  1.00-1.45           
Published>2003   1.00  0.89-1.13   1.01  0.84-1.22   1.74  1.03-2.94   1.17  0.92-1.48           
Intestinal histotype   1.76  1.12-2.75   1.12  0.85-1.47   0.97  0.70-1.35   1.72  0.92-3.21       0.04§  1.10  0.64-1.89 
Cardia                           0.03§  0.91  0.53-1.55 
Advanced                           0.35§  1.48  1.01-2.16 
Poor diferentiated                           <0.01§  2.25  0.21-23.84 
  Interactions                               
H. pylori infected   1.41  0.96-2.07   0.67  0.46-0.98         4.81  1.4-17.28           
 













p het.  OR  95% CI  p het.  OR  95% CI  p het.  OR  95% CI  p het.  OR  95% CI  p het.  OR  95% CI  p het.  OR  95% CI 
Overall  0.03  1.36  0.82-2.25  <0.01  1.24  1.00-1.54  0.48  1.09  0.97-1.21  0.37  1.52  1.31-1.77  0.93 0.94  0.65-1.35  0.01  0.98  0.78-1.24 
Caucasian  0.46  0.42  0.05-3.85   1.22  1.04-1.43  0.87  1.27  1.03-1.56  >0.1  1.34  0.90-1.99   -  -  0.29  1.45  1.06-1.97 
Asian  0.02  1.44  0.85-2.42   1.19  0.81-1.75  0.33  1.02  0.89-1.18  >0.1  1.64  1.36-1.97  >0.1 0.81  0.43-1.51  0.27  0.81  0.67-0.99 
High quality  0.08  2.14  0.96-4.74      0.41  1.23  1.04-1.45                 
Population controls       0.02  0.95  0.90-1.73  0.29  1.09  0.92-1.29                 
Power >80% RR=2       0.12  1.05  0.87-1.28  0.27  1.08  1.24-0.47                 
Genot.  Methods       <0.01  1.20  0.97-1.47                      
Cardia                   >0.1  1.51  1.11-2.05  >0.1 0.99  0.43-2.28      
Pooled analysis                    0.06  1.49  1.14-1.95  0.50 0.90  0.69-1.34      
  Interactions                                     
Eversmokers 0.21  1.14  0.51-2.53   2.93°  1.56-5.47  0.03  1.54  0.95-2.48                
Alcohol consumers  0.77  1.26  0.58-2.75                         
GSTT1 null  0.88  1.85  0.68-5.02                         
GSTM1 null  0.04  4.93  0.73-33.08      0.58°  1.95  1.42-2.67                
   5.36° 1.01-28.47                          
§ Cases-only, category vs opposite category. °Individuals exposed to both risk factors vs double unexposed: GSTM1 null eversmokers vs GSTM1 wild-type neversmokers; GSTM1 
and GSTT1 null vs GSTM1 and GSTT1 wild-type; CYP2E1 c2c2 and GSTM1 null vs CYP2E1 and GSTM1 wild-type; ^p for heterogeneity from Q-test when reported from the meta-
analysis. A Systematic Review of Meta-Analyses  Current Genomics, 2008, Vol. 9, No. 6    365 
  These results were confirmed by the meta-analysis per-
formed by Wang et al. [23], which included a larger number 
of cases and controls (Fig. 1). An overall OR of 1.26 
(95%CI: 1.03-1.55; p for heterogeneity <0.001) has been 
reported (Table 1) for carriers of T allele vs CC. A meta-
regression analysis suggests no effect of ethnicity, cancer 
histopathology, Helicobacter pylori infection and item re-
lated to methodological quality of included studies (p>0.1), 
although significantly higher risk of gastric cancer resulted 
for the intestinal subtype (OR = 1.76, 95%CI: 1.12-2.75) as 
well as for studies with characteristics related to low meth-
odological quality (Table 1). Interaction analysis with Heli-
cobacter pylori infection (p value from meta-regression = 
0.73) showed results similar to main analysis in general 
population (Table 1). In subgroup analyses, a significantly 
higher risk of gastric cancer resulted for the intestinal sub-
type (OR = 1.76, 95%CI: 1.12-2.75, Table 1) as well as for 
unmatched studies, those using a genotyping technique other 
than Polymerase Chain Reaction (PCR)- Restriction Frag-
ment Length Polymorphisms (RFLP), and the papers pub-
lished before 2003 (data not shown). 
  The meta-analysis performed by Kamangar et al. [21] 
reported a meta-ORs for CT heterozygotes of 1.07 (95%CI: 
0.91-1.25; p for heterogeneity <0.001), and TT homozygotes 
of 1.16 (95%CI: 0.95-1.42; p for heterogeneity <0.001) 
compared with wild-type allele homozygotes (Fig. 1). Sub-
group analyses according to ethnicity, tumor location, hys-
tological subtype, or possibility of bias due to genotyping 
provided no explanation of the heterogeneity and no signifi-
cantly different results, despite confirming the trends shown 
in the other two meta-analyses [22,23].  
IL-1B -31C  
  The meta-analysis of Camargo et al. [22], including 14 
studies, suggested as appropriate the dominant genetic 
model, and showed a non-significantly increased risk of gas-
tric cancer for those carrying C variant allele of IL-1B -31 
compared with those wild-type homozygotes (OR = 1.04, 
95%CI: 0.83-1.29; p for heterogeneity <0.001). Subgroup 
analyses (ethnicity, subsite, hystologic subtype, age and sex 
matching, quality of the included studies and sample size) 
failed to find out the heterogeneity source (data not shown). 
The meta-analysis of Wang et al. [23] which included 21 
studies showed the absence of a significant association with 
gastric cancer (OR = 1.00, 95%CI: 0.82-1.22, p for hetero-
geneity <0.001). Meta-regression analyses showed that eth-
nicity, cancer histopathology, item related to methodological 
quality of included studies did not affect the systemic results 
(p>0.05, although for study quality p = 0.06), while Helico-
bacter pylori infection seems to have some impact in hetero-
geneity (p = 0.03), with -31C carriers having statistically 
significant decreased risk with respect to wild-type homozy-
gotes among subgroups of HP infected (OR = 0.67; 95%CI: 
0.46-0.98; Table 1). Lastly, the meta-analysis of Kamangar 
et al. [21], which including 22 studies, did not report signifi-
cant association neither for variant CC individuals (OR = 
0.98, 95% CI: 0.78-1.21), nor for heterozygotes (OR = 0.99, 
95% CI: 0.83-1.19; Fig. 1) compared with wild-type homo-
zygotes. Subgroup analyses (ethnicity, hystological subtype 
and cancer site) did not provide significant results (data not 
shown). 
IL-1B +3954T  
  Two meta-analyses summarized the association between 
IL-1B +3954T polymorphism and gastric cancer (Fig. 1) 
(Wang et al. [23], 10 studies; Camargo et al. [22], 8 studies). 
The small number of subjects carrying the variant TT geno-
type prevented the analysis of homozygous individuals, 
therefore a dominant genetic model was assumed [22]. Ac-
cording to both meta-analyses, individuals carrying +3954T 
mutant allele had an increased gastric cancer risk compared 
with +3954CC individuals, however not statistically signifi-
cant (Camargo et al.: OR = 1.26, 95%CI: 0.87-1.24; p for 
heterogeneity <0.001; Wang et al.: OR = 1.37, 95%CI: 0.94-
2.00;  p for heterogeneity <0.001). None of the performed 
subgroup analyses explained the potential sources of hetero-
geneity, with heterogeneity decreasing only in subgroups 
including a limited number of studies and p value from meta-
regression indicating a slight effect in heterogeneity for eth-
nicity (p = 0.04; non-significant ORs in subgroups). No in-
teraction analysis was performed because of data unavail-
ability. 
IL-1RN *2  
  The association between IL-1RN*2 variant allele and 
gastric cancer has been summarized from Camargo et al. 
[22], Wang et al. [23], and Kamangar et al. [21] (Fig. 1). The 
meta-analysis from Camargo et al. [22] suggested the reces-
sive model as the most appropriate. Homozygotes for *2 
allele have a non-significantly increased risk of gastric can-
cer (OR = 1.29, 95% CI: 0.82-2.02, p for heterogeneity 
<0.01) compared with carriers of long alleles (L), neverthe-
less a minor but slight statistically significant increase of 
gastric cancer risk resulted for carriers of the IL-1RN*2 allele 
(OR = 1.17, 95%CI: 1.00-1.37, p for heterogeneity <0.01) 
compared with the LL homozygotes. The subgroups analyses 
by ethnicity, subsite, hystologic subtype, age and sex match-
ing, quality of included studies and sample sizes were per-
formed for each of the genetic model used, showing de-
creased heterogenity among Asians and Hispanics (recessive 
model) and in subgroups of age and sex matched studies or 
with population-based controls (dominant model; data not 
shown). When considering only the intestinal subtypes of 
gastric cancer, both models provided increased risk, statisti-
cally significant only in the recessive model (OR = 2.26, 
95%CI: 1.08-4.74). The meta-analysis of Wang et al. [23] 
reported a meta-OR of 1.20 (95%CI: 1.01-1.41; p for hetero-
geneity <0.01) for IL-1RN*2 carriers compared with IL-1RN 
homozygous wild-type individuals. Meta-regression includ-
ing effect estimates and ethnicity, histopathology, age and 
sex matching, quality of included studies control source, 
publication time and Helicobacter pylori infection showed 
that possible source of heterogeneity are Helicobacter pylori 
infection (p<0.001), with ORs that became significant in 
both Helicobacter pylori infected (OR = 4.81, 95%CI: 1.40-
17.28) and uninfected (OR = 1.83, 95%CI: 1.17-2.86). Geno-
typing methods also represents a major issue for this poly-
morphism, with only studies using PCR-RFLP methods con-
firming the main result (data not shown). Analyses from 
genotype contrasts by Kamangar et al. [21] showed ORs of 
1.15 (95%CI: 0.96-1.38) and 1.23 (95%CI: 0.79-1.92) for IL-
1RN *2 heterozygotes and for *2*2 homozygotes versus LL 
individuals, respectively. Subgroup analyses (ethnicity, hys-366    Current Genomics, 2008, Vol. 9, No. 6  Gianfagna et al. 
tological subtype and cancer site) did not provide significant 
results. 
Interleukin-8 
  Interleukin-8 (IL-8) is a member of the family of 
chemokines. Initially characterized for its leukocyte chemo-
tactic activity it is mainly involved in the initiation and am-
plification of acute inflammatory reactions as well as the 
maintenance of chronic inflammatory processes [43]. The 
IL-8 cytokine is also involved in the gastric inflammatory 
response to Helicobacter pylori infection, through the re-
cruitment and activation of immune cells and the stimulation 
of Reg protein expression which is a potent growth factor for 
gastric mucosal cells [44]. In addition it has been described 
that IL-8 has tumorigenic and proangiogenic properties [45]. 
The gene coding for IL-8 exhibits several functional poly-
morphisms, fifteen of them have been characterized [46]. 
Among these polymorphisms the presence of IL-8 -251 T/A 
in the transcription start site exerts a great influence on IL-8 
production and an increased transcriptional activity of the 
IL-8 promoter was confirmed in an in-vitro assay [47, 48]. 
The frequency of the mutant allele -251A varied signifi-
cantly among different ethnic groups, ranging from 38-51% 
in Europeans [49,50] and 30-42% in Asians [51,52].  
  A recently published meta-analysis on IL-8 -251A and 
gastric cancer included 8 case-control studies [19] (Fig. 1). 
The combined OR was not significant for the individuals 
carrying the -251A allele compared with the homozygous 
wild-type genotype (OR = 1.12, 95%CI: 0.90-1.40; p  for 
heterogeneity = 0.003). The heterogeneity decreased when 
one study was excluded from the analysis, resulting in a sig-
nificantly higher risk for gastric cancer among carriers of the 
variant allele (fixed effect OR = 1.21, 95% CI: 1.06-1.39; p 
for heterogeneity =0.05).  
Cytochrome P450 2E1 
  Cytochrome P450 2E1 (CYP2E1), a member of the cyto-
chrome P-450 superfamily, is a naturally ethanol-inducible 
Phase I enzyme. It is mainly involved in the metabolic acti-
vation of low molecular weight compounds such as N-
nitrosamines as well as in alcohol metabolism [53,54]. N-
nitrosamines are formed endogenously in the stomach and 
are present in different environmental factors including to-
bacco smoke and some dietary compounds [55]. CYP2E1 
gene is expressed nearly ubiquitously [56]. Two point muta-
tions in the 5’-flanking region (PstI, RsaI), which are in close 
linkage disequilibrium, are known to alter the gene transcrip-
tional activity [53]. The resulting c2 variant allele (7% of 
Caucasians, 36% of Asians) [57,58] is associated with a 
higher protein production. The association between CYP2E1 
polymorphisms and gastric cancer was firstly investigated by 
Kato  et al. in 1995 [59]. The only one meta-analysis on 
CYP2E1 PstI/RsaI and gastric cancer [26] included 13 stud-
ies published before 2005 (Fig. 1). The meta-analysis (Table 
1) showed an overall OR of gastric cancer risk of 0.97 
(95%CI: 0.79-1.18; p for heterogeneity = 0.01) for c2 variant 
allele carriers, and 1.36 (95%CI: 0.82-2.25; p for heterogene-
ity = 0.03) for c2 homozygotes compared with wild-type c1 
homozygotes. Stratifying the results for ethnicity and quality 
score, a decreased heterogeneity in Caucasians (p for hetero-
geneity = 0.53 and 0.46 for c2 carriers and homozygotes, 
respectively) and high quality studies (p for heterogeneity = 
0.08 for both models) was observed (Table 1). High quality 
studies among Asians showed a significant increased risk of 
gastric cancer both among c2 heterozygotes and c2 homozy-
gotes (p for heterogeneity = 0.71 and 0.38). Authors of the 
meta-analysis performed some gene-gene and gene-
environment interaction meta-analysis by using individual 
level data provided by some authors of the studies included. 
No significant association was detected from gene-environ- 
ment (smoking, alcohol) interaction meta-analysis, despite 
the biological plausibility, while an OR of 5.36 (95%CI: 
1.01-28.47) for gastric cancer appeared for CYP2E1 c2 ho-
mozygotes with GSTM1 null genotype, compared with indi-
viduals carrying both wild-type genotypes. In these interac-
tion analyses the heterogeneity decreased, until a minimum 
value (p for heterogeneity = 0.58) in the gene-gene interac-
tion analysis (double homozygotes contrasts).  
Glutathione S-Transferase  
  Glutathione S-tranferase (GST) is a family of genes, 
mainly involved in cell protection against electrophiles, in-
cluding several environmental carcinogens, as well as en-
dogenous products of oxidative stress [60]. These phase II 
enzymes bind glutathione, a nucleophilic tripeptide, to a 
wide spectrum of carcinogens, facilitating their detoxifica-
tion [8]. Three major GST subfamilies are widely expressed 
in humans: GSTM (μ), GSTT () and GSTP () with overlap-
ping substrate specificities [61,62]. GSTM1 and GSTT1 
genes  exhibit homozygous deletion (null genotype) poly-
morphisms. Individuals carrying one of these variants have 
no enzyme activity, and thus are more susceptible to car-
cinogens such as benzo[]pyrene-7,8-diol epoxide, the acti-
vated form of benzo[]pyrene, and smaller reactive hydro-
carbons, such as ethylene oxide and diepoxybutane [60,63], 
which could lead to environmentally-induced cancer suscep-
tibility [64].  
GSTM1 null 
  Glutathione S transferase M1 (GSTM1) is mainly ex-
pressed in liver, brain and stomach. The GSTM1 null geno-
type is found in 10-60% of individuals ranging from 50% in 
Caucasians and Asians to 25% in Africans [29]. The associa-
tion between GSTM1 null genotype and gastric cancer was 
firstly investigated by Strange et al. in 1991 [65]. Two meta-
analyses summarizing the results of individual studies are 
published and reported in Table 1.  
  The first meta-analysis evaluating the association be-
tween GSTM1 status and gastric cancer included 15 primary 
studies in English language and was published in 2005 [29]. 
The meta-OR was 1.24 (95%CI: 1.00-1.54; p for heterogene-
ity <0.01) (Fig. 1). The heterogeneity slightly decreased after 
stratifying by ethnicity (Asians, p for heterogeneity = 0.02), 
source of controls (hospital, p for heterogeneity = 0.06) and 
study power (>80% for OR=2.0 and =0.05, p for heteroge-
neity = 0.12) (Table 1). Caucasians showed a significantly 
increased risk (OR = 1.22, 95% CI: 1.04-1.43,) while studies 
with at least 80% power provided the lowest estimate (OR = 
1.05, 95% CI: 0.87-1.28). As for gene-environmental analy-
sis, the meta-analysis showed an OR of 2.93 (95%CI: 1.56-
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GSTM1 null compared to never-smokers with GSTM1 wild 
type genotype (Fig. 1 and Table 1). Data on other types of 
interacting carcinogens, such as Helicobacter pylori infec-
tion and dietary compounds, were not available to perform 
any subgroup meta-analyses. 
GSTT1 null 
  Glutathione S transferase T1 (GSTT1)  is mainly ex-
pressed along the human gastrointestinal tract. The null 
genotype of GSTT1 is present in 13-31% among Caucasians 
and 36-55% among Asians. The association between GSTT1 
null genotype and gastric cancer was firstly investigated by 
Deakin et al. in 1996 [66]. Two meta-analyses exploring this 
association, were contemporarily published in 2006 (Fig. 1) 
[27,28]. The meta-analysis of Saadat [27] included 16 stud-
ies and reported an OR of 1.06 (95%CI: 0.94-1.19; p for het-
erogeneity > 0.05) for the association between GSTT1 null 
genotype and gastric cancer. The meta-analysis of Boccia et 
al. [28] included 18 articles published in all languages and 
showed similar results (OR = 1.09, 95%CI: 0.97-1.21; p for 
heterogeneity = 0.48). According to Saadat [27], among the 
stratified analyses carried out for ethnicity, source of con-
trols, sample size and smoking status, the subgroup of Cau-
casian studies showed a statistically significant increased 
risk of gastric cancer (OR = 1.27, 95%CI: 1.03-1.57), also 
confirmed by Boccia et al. (p for heterogeneity = 0.87) [28].  
  Both meta-analyses reported the absence of statistically 
significant association after restricting the analysis to the 
source of control or studies’ power, however Boccia et al. 
[28] showed a statistically significant association after re-
stricting the analysis to high quality studies (OR = 1.23, 
95%CI: 1.04-1.45; p for heterogeneity = 0.41). As for gene-
environment interaction analysis, Saadat [27] reported an OR 
of 1.27 (95% CI: 0.94-1.72; p>005) for GSTT1 null indi-
viduals compared to those with the normal genotype ever 
smokers. The identical subgroup analysis was performed by 
Boccia et al. [28], with the addition of data from two studies 
providing individual data, and results showed an OR of 1.54 
(CI 95%: 0.95-2.48; p for heterogeneity = 0. 03) [28]. As for 
gene-gene interaction analysis, data on GSTT1 and GSTM1 
genotypes were combined in the two meta-analyses, using as 
reference group those carrying both homozygous wild geno-
types. Saadat [27] extracted data from 4 studies and showed 
a significantly increased risk for individuals with the com-
bined presence of GSTM1 and GSTT1 null genotypes if 
compared to those with both wild-type variant (OR = 2.08; 
95% CI: 1.42-3.10). A similar result (OR = 1.95, 95% CI: 
1.42-2.67; p for heterogeneity = 0.58) was shown by Boccia 
et al. [28], by pooling additional data obtained asking to the 
authors (total 7 studies). Saadat described an additive effect 
for GSTT1 and GSTM1 genotypes, taking into account the 
effects of each of the functional polymorphisms on gastric 
cancer risk [27]. Only few studies collected data on Helico-
bacter pylori infection and food consumption, in a way that 
was not enough to perform any subgroup meta-analyses. 
Methylenetetrahydrofolate Reductase 
  Methylenetetrahydrofolate reductase (MTHFR) is a key 
enzyme in folate metabolic pathway that irreversibly cata-
lyzes the conversion of 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate, the primary circulating form of fo-
late and a cosubstrate for homocysteine methylation to me-
thionine. Folic acid, a form of the water-soluble Vitamin B9, 
is a precursor of the metabolic pathway leading to DNA 
methylation which functions as a regulatory mechanism of 
gene expression. In addition folate plays an important role in 
transferring single-carbon methyl units during the synthesis 
of DNA and RNA and it is also involved in DNA repair. 
Folate intake is provided by diet and serum folate levels 
could be impaired by alcohol drinking, smoking habits and 
altered activity of several enzymes, such as MTHFR, serine 
hydroxymethyltransferase, thymidylate synthase and me-
thionine synthase [67-69]. MTHFR is expressed ubiquitously 
and two functional polymorphisms, C677T and A1298C, 
have been identified [70]. Frequencies of individuals carry-
ing the 677T allele are around 50% in Asians, 44% in Cau-
casians and 23% in African-Americans. The less frequent 
1298C allele is present in 40% of Caucasians, 30% of Asians 
and 30% of African-Americans. Heterozygotes (CT) and 
homozygotes (TT) for C677T mutant allele have respec-
tively 65% and 30% of the enzyme activity compared with 
individuals with the wild-type genotype, while 1298CC ho-
mozygotes have nearly 60% of the normal enzyme activity 
[70,71]. Individuals with the TT genotype for MTFR 677 
have significantly lower plasma folate levels than those with 
the wild-type genotype, while for the MTFR 1298 variant the 
evidence is inconsistent [72]. Low folate levels might induce 
uracil misincorporation into DNA, which could lead to 
chromosomal breaks and mutations, and DNA hypomethyla-
tion, which results in altered gene expression and DNA con-
formation [73].  
MTHFR 677T 
 The  association  between  MTHFR polymorphisms and 
gastric cancer was firstly investigated by Shen et al. in 2001 
[74]. In the last two years, three meta-analyses and one 
pooled analysis were published on MTHFR polymorphisms 
and gastric cancer [17,24,25]. According to the meta-
analysis of Larrson et al. [25], which included 9 studies, in-
dividuals with the MTHFR 677TT genotype showed a higher 
risk of gastric cardia adenocarcinoma (OR = 1.90;95%CI: 
1.38-2.60) and gastric cancer (OR = 1.68;95%CI: 1.29-2.19) 
compared with those wild-type homozygotes [25]. No sig-
nificant heterogeneity was detected among the studies (p for 
heterogeneity = 0.29 and 0.12, respectively). The meta-
analysis published by Zintzaras [24], including 8 studies 
(1584 cases and 2785 controls), reported similar results (data 
not shown). The least heterogeneity resulted for the recessive 
model, with the TT individuals having an increased gastric 
cancer risk compared with carriers of the C allele (OR = 
1.47, 95% CI: 1.26-1.73; p for heterogeneity = 0.66). Strati-
fication by gastric cancer site failed to decrease heterogene-
ity, while for East Asian studies a very low heterogeneity 
was observed (p for heterogeneity = 0.96 in the recessive 
model). The meta-analysis by Boccia et al. [17] which in-
cluded 16 studies produced an overall OR of 1.52 (95% CI: 
1.31-1.77; p for heterogeneity = 0.37) for gastric cancer and 
MTHFR TT genotype compared to the 677 CC. The sub-
group analysis are reported on Table 1. Since no data for 
interaction analyses were available to perform subgroup 
meta-analyses according to folate, alcohol and smoking, a 
pooled-analysis was carried out by Boccia et al. [17]. Data 
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cases and 1549 controls were pooled for C677T and A1298C, 
respectively. Overall, the pooled analysis showed that 
MTHFR 677 TT individuals have an OR of 1.49 (95%CI: 
1.14-1.95; p for heterogeneity = 0.06) for gastric cancer, thus 
confirming previous meta-analyses based on an unadjusted 
estimates. Sensitivity analyses based on ethnicity and gastric 
cancer site provided similar results, with a lower heterogene-
ity among East Asians (p for heterogeneity = 0.34). When 
results from the pooled analysis of four studies on C677T 
were stratified according to folate levels, results showed an 
increased risk among individuals with low levels (OR = 
2.05; 95% CI: 1.13-3.72; p for heterogeneity = 0.96) respect 
to those with high folate levels (OR = 0.95; 95% CI: 0.54-
1.67 p for heterogeneity = 0.86; p value among the two strata 
= 0.06). No interaction was detected from the stratified 
analyses according to alcohol and smoking habits, with de-
creased heterogeneity only in the unexposed subgroups (p 
for heterogeneity = 0.84 and 0.49; Table 1). 
MTHFR 1298C 
  Absence of statistically significant association of 1298C 
variant allele and gastric cancer was reported in all genetic 
models, from Zintzaras (4 studies, all from East-Asiatic 
populations) [24] and Boccia et al. (7 studies) (Table 1) [17]. 
The subgroup analyses according to ethnicity and tumour 
site performed by Boccia et al. [17] provided similar results, 
with no evidence of heterogeneity. Identically, the meta-
analysis by Zintzaras [24] showed absence of association 
between MTHFR A1298C polymorphism and gastric cancer 
even when restricting the analysis to studies conducted 
among East-Asians or studies whose controls were in Hardy-
Weinberg equilibrium.  
p53 
 The  p53 tumor suppressor gene is one of the most com-
monly mutated genes in all types of human cancer and en-
codes a transcription factor involved in cell cycle regulation. 
The p53 acts as a tumor suppressor gene by inducing cell 
cycle arrest or apoptosis and requires loss of function muta-
tions for cancer development. Even if p53 gene is highly 
polymorphic, with at least 13 single nucleotide polymor-
phisms described [75], the p53 exon4 Arg72Pro polymor-
phism is the only whose role has been extensively studied in 
relation to gastric cancer. A polymorphism in this codon, 
which consists in a single base pair change of either arginine 
(Arg) or proline (Pro), has been suggested to modulate p53-
dependent apoptosis and modify sensitivity to chemothera-
peutic agents [76,77]. The alterations in exon 4 of the p53 
gene in gastric cancer were firstly investigated by Shepherd 
et al. in 2000 [77], who reported the following genotype fre-
quencies: Arg/Arg (54%) Arg/Pro (33%) Pro/Pro (14%). The 
most intriguing aspect of the initial study is that the genotype 
of the codon 72 polymorphic site varied significantly with 
race (p for heterogeneity = 0.0001) as follows: 64% of 
whites had the Arg/Arg genotype compared with 24% of 
blacks [77].  
  The association between p53  codon 72 polymorphism 
and gastric cancer was firstly investigated by Hiyama et al. 
in 2002 [78]. A meta-analysis on p53 exon4 Arg72Pro 
polymorphism and gastric cancer including 12 case-control 
studies has been recently published (Fig. 1 and Table 2) [20]. 
The combined results showed no significant difference in 
genotype distribution between gastric cancer cases and con-
trols, with all models presenting heterogeneity and the reces-
Table 2.  Population Attributable Risk (PAR)° of Gastric Cancer Related to the Studied Polymorphisms 
Asians Caucasians 
Polymorphism 
PAR %  95% CI§  PAR %  95% CI 
IL-1B -511T carrier status   10.2  (-9.4, 26.2)  18.3  (-5.2, 36.4) 
IL-1B -31C carrier status  -6.8  (-37.6, 15.4)  5.3  (-19.3, 23.6) 
IL-1B +3954T carrier status  6.7  (-24.1, 20.7)  5.3  (-11.4, 18.5) 
IL-1RN *2 carrier status  1.2  (-6.8, 7.4)  10.8  (2.3, 21.8) 
IL-8 -251A carrier status  12.0  (-6.5, 28.2)  -  - 
GSTM1 null  9.0  (-18.9, 28.3)  9.6  (0.8, 19.0) 
GSTT1 null  0.9  (-8.2, 8.8)  4.3  (0.0, 12.4) 
CYP2E1 PstI/RsaI c2c2   1.8  (-2.0, 4.7)  -  - 
MTHFR 677TT  10.0  (4.7, 16.4)  9.9  (-8.7, 26.5) 
MTHFR 1298CC   -16.0  (-100, 28.7)  - - 
p53 codon 72 Arg/Arg ^  -3.9  (-11.3, 0.34)  4.1 (-5.7,  15.2) 
E-cadherin -160A carrier status  -9.2  (-26.0, 0.9)  18.5 (1.1,  33.4) 
°PAR computed using meta-OR (wild-type homozigotes as reference) and the proportion of exposed cases (inverse-variance weighted mean derived from primary studies included in 
the meta-analyses); § confidence interval from Bonferroni inequalities [16]; ^ OR using Arg/Pro and Pro/Pro individuals as reference. A Systematic Review of Meta-Analyses  Current Genomics, 2008, Vol. 9, No. 6    369 
sive model giving the highest OR (1.21, 95%CI: 0.92-1.58; p 
for heterogeneity = 0.01). Heterogeneity was tested by sub-
group analyses on ethnicity, tumour location, stage, Lauren’s 
classification and histological type. A significantly lower 
frequency of the Arg/Arg genotype in gastric cancer cases 
compared with controls was reported among Asians (OR for 
Arg/Arg versus carriers of the mutant allele = 0.84, 95%CI: 
0.72-0.99), while not among Caucasians. Considering cases-
only analyses performed on Asiatic case-control studies, a 
significantly higher frequency of variant homozygous geno-
type was found for gastric cardia cancer with respect to other 
locations (OR = 3.20, 95%CI: 1.46-7.01), and for advanced 
stages (III/IV) respect to those with early stages (I/II) (OR = 
1.48, 95%CI: 1.01, 2.16; Table 1). Data on other potential 
carcinogens such Helicobacter pylori infection and diet were 
insufficient to perform any subgroup meta-analyses. 
E-cadherin 
 The  E-cadherin gene encodes a transmembrane glycopro-
tein, mainly involved in the establishment and maintanance 
of intercellular adhesion, cell polarity and the normal archi-
tecture of epithelial tissues [79] as well as in cell signaling in 
conjunction with cytoplasmic catenin proteins [18]. E-
cadherin glycoprotein, as a calcium-dependent intercellular 
adhesion molecule, is localized on the surfaces of epithelial 
cells in regions of cell-cell contact, commonly known as 
adherens junctions [80]. The loss of the adhesive function of 
E-cadherin is a critical step in tumour development and pro-
gression mediating the transition to an invasive phenotype in 
human epithelial cancers [81]. Li et al. [81] identified a C/A 
single nucleotide polymorphism at -160 base pairs from the 
transcriptional start site of the E-cadherin gene promoter, 
showing that the A allele decreased the transcriptional effi-
ciency by 68% if compared to the wild-type C allele, proba-
bly due to a stronger transcriptional factor binding activity of 
the C allele than the variant allele A. Therefore the -160 C/A 
polymorphism might alter E-cadherin expression, increasing 
susceptibility to epithelial cancers. The frequency of the mu-
tant allele -160A varied significantly among different ethnic 
groups and geographic areas, ranging from 43.4-23.3% of 
Europeans and 0-61% in Asians [18].  
  The association between E-cadherin polymorphism and 
gastric cancer was firstly investigated by Wu et al. in 2002 
[82]. A recently published meta-analysis on E-cadherin poly- 
morphism and gastric cancer [18], including 9 case-control 
studies, was conducted to explore the association between 
gastric cancer and the -160 C/A polymorphism (Fig. 1). The 
combined OR was not significant for the -160A allele carri-
ers compared with the homozygous wild-type genotype (OR 
= 0.98, 95%CI: 0.79-1.16; p for heterogeneity = 0.01). The 
heterogeneity substantially decreased when Asian and Euro-
pean were analysed separately, resulting in a significantly 
higher risk for gastric cancer among carriers of the variant A 
allele among Caucasians (OR = 1.45, 95% CI: 1.06-1.97; p 
for heterogeneity = 0.29), and a decreased risk among Asians 
(OR = 0.81, 95% CI: 0.67-0.99; p for heterogeneity = 0.27; 
Table 1).  
SOURCES OF HETEROGENEITY 
  An important aim of meta-analyses is to assess the extent 
to which different studies provide similar or dissimilar re-
sults, which is usually assessed by statistical tests such as Q 
or  I
2 statistics [83], and to explain the sources. Statistical 
heterogeneity usually reflects variability in the results of 
different studies on the same question, which might not al-
ways represent a bias. Genetic association could, in fact, 
have different strength in different populations and different 
settings. Nevertheless, some authors listed potential reasons 
for inconsistency in results of genetic associations [84]. 
Among them, true variation of underlying association be-
tween populations, allelic associations that might vary be-
tween study setting, effect modification by other genetic 
variants or environmental risk factors, misclassification of 
the outcome, population stratification, and finally variation 
in power between studies. The present systematic review 
shows that in the published meta-analyses on polymorphisms 
and gastric cancer the potential sources of heterogeneity was 
investigated, and decreased heterogeneity among homogene-
ous ethnic groups and among individuals exposed to the 
same environmental risk factor resulted in many cases. 
  When results were stratified for ethnicity, heterogeneity 
strongly decreases for IL-1 -511T polymorphisms [22], IL-1 
+3954T [22,23], E cadherin -160A [18], GSTT1 null [28] 
and MTHFR 677T in the pooled analysis [17], as possibly for 
+3954T [23]. Wide differences in allele frequencies have 
been reported for the mentioned polymorphisms among eth-
nic groups. Study characteristics as age/sex matching, source 
of controls, genotyping methods, are the second most studied 
potential source of heterogeneity. Quality scoring systems of 
the primary studies included in a meta-analysis were recently 
suggested by some authors, aiming to provide a tool for dis-
tinguishing between high an low quality studies, with most 
of them taking into account the previously listed study char-
acteristics. Four meta-analyses [22,23,26,28] included in this 
review used a quality scale system and results show that 
stratification for quality score decreased heterogeneity for 
IL-1 -31, IL-1 -511 and CYP2E1 PstI/RsaI. Furthermore, the 
studies scored as of high quality reported stronger effect es-
timates than those of low quality in 3 [22,26,28] out of 4 
meta-analyses (Table 1).  
  Subgroup analyses according to environmental co-
exposures showed a decreased statistical heterogeneity, as 
expected. The final effect of a functional genetic variant on a 
certain disease is expected to change in presence of its envi-
ronmental substrate, so that the effect estimate might be ex-
tremely heterogeneous among studies if this aspect is not 
taken into account. In the reviewed meta-analyses, stratified 
analyses according to environmental exposures biologically 
related to the polymorphisms showed a decreased heteroge-
neity in almost all the instances (Table 1). Lastly, interaction 
between two polymorphisms might be an additional source 
of heterogeneity, and this was investigated in 3 meta-
analyses [26-28] on metabolic genes (Table 1). The sub-
group analyses exploring gene-gene interaction were per-
formed by comparing the effect of one polymorphism after 
stratifying for a second genetic risk factor, or by comparing 
homozygotes for both the unfavourable variants with double 
wild-type homozygotes. In both instances the heterogeneity 
decreased and the ORs increased, although reaching statisti-
cally significant results only when comparing opposite ho-
mozygotes [26-28]. Carcinogens are usually detoxified by 
several enzymes involved in the same pathway, so that the 370    Current Genomics, 2008, Vol. 9, No. 6  Gianfagna et al. 
contemporarily lack of two or more enzyme functions could 
exponentially increase the effect of the carcinogens on dis-
ease risk. The identified synergistic interaction among GSTs 
null genotypes as well as the relationship between GSTM1 
and CYP2E1 unfavourable variants suggest that a wide por-
tion of gastric cancer could be attributable to the inheritance 
of both unfavourable polymorphisms. Unluckily, these are 
the only reported gene-gene interaction meta-analyses, which 
were clearly limited from the few amount of original gene-
gene interaction data from the individual studies. As exam-
ple, though 17 of 18 published studies collected data on both 
GSTM1 and GSTT1 genotypes, only 5 authors reported case-
control data according the two gene variants, thus limiting 
the power of subgroup meta-analysis. In this sense, large 
pooled analysis on gene-gene interaction and ad-hoc multi-
ple genotyping conducted within consortia are strongly de-
sirable. 
PUBLICATION BIAS  
  Publication bias may be seen as a type of selection bias 
afflicting the scientific literature, stemming from that evi-
dence that studies showing ‘significant’ results are more 
likely to be published than those presenting ‘negative’ re-
sults. The most reasonable explanations for this phenomenon 
is that authors may fail to write ‘negative’ papers and submit 
them to journals, as results are reviewed less favourably, or 
because editors simply don’t want to publish negative re-
sults. Additionally, papers reporting ‘positive’ results are 
more frequently published on international journals while 
‘negative’ results are more easily published on local journals 
[85].  
  An accurate bibliographic search that foresee the retrieval 
of local literature can help minimizing this bias, however 
ascertaining the extent of publication bias is difficult, and 
typically we have no idea to what extent unpublished data 
distorts the literature. In almost all the included meta-
analyses, publication bias was evaluated by visual inspection 
of funnel plot and/or with any asymmetry test, with observed 
asymmetry only in limited cases and of limited extent. How-
ever, asymmetry tests have limited power when the number 
of included studies is small. In this review we aimed to iden-
tify the presence and the source of publication bias, and a 
funnel plot was derived pooling all the primary data included 
in the meta-analyses, using the ratio of the study OR for the 
unfavourable polymorphism and the OR of the correspond-
ing meta-analysis. This computation allows to have compa-
rable values for different studies datasets included in the 
meta-analyses. A slight asymmetry resulted by visual inspec-
tion (Fig. 2) and was confirmed by Egger (p = 0.029.) and 
Begg tests (p = 0.005). We also aimed to explore if the pub-
lication period affected the publication bias, and results show 
that the small outlier studies reporting statistically significant 
results were mainly published as first, while smaller studies 
which appear in the right side of the plot are the recently 
published ones (Fig. 2, bottom left and right, respectively). A 
time-dependent asymmetry was confirmed by Egger and 
Begg tests, with p values of 0.002 and 0.008 in the subgroup 
of papers published during the second period of time, and 
0.14 and 0.72 in the first period, respectively.  Publication 
bias could also occur in the subgroup analyses, when col-
lected data are reported by the authors in the full-text or indi-
cated by the indexers in record field of bibliographic data-
bases only if they are interesting. However, this issue is 
solved in the meta-analyses directly asking authors of the 
published papers to provide individual data [22,26,28]. 
POWER  
  The lack of statistically significant results could be firstly 
due to the low power of some meta-analysis, which depends 
on the number of available studies and their results. MTHFR 
677T variant allele seems to confer an increased risk of 50%, 
so the power to detect this association could reached by in-
cluding even a few number of studies, while statistical sig-
nificance for polymorphisms whose expected OR is 1.20 
clearly needs a higher number of primary studies. In contrast 
the slight association between IL-1 polymorphisms and gas-
tric cancer risk has been detected because many primary 
studies have been published on this issue.  
  A comprehensive bibliographic search should be per-
formed to provide a precise summary estimate given the ex-
isting studies on the same topic, avoiding, at the same time, 
selection bias. This is particularly true for subgroup analyses, 
which can be performed o the basis of data which could be 
collected and/or reported by few studies. In order to perform 
subgroup meta-analyses to explore gene-gene and gene-
environment interaction with a greater power and avoid se-
lection bias, contacting the authors of the published paper to 
ask for the unreported data or the entire dataset is highly 
recommended. Meta-analyses on CYP2E1 and GSTT1 genes 
obtained data on environmental and genetic co-exposures 
from the authors of the primary studies, and provided more 
precise estimates on GSTT1 and smoking interaction [28], 
and CYP2E1 and GSTs interaction [26]. The pooled analysis 
of MTHFR C677T and A1298C used the original data from 
around 50% of the published primary studies, however re-
sults did not differ from those of the meta-analysis of all 
published reports. Additional to the meta-analysis, however, 
the pooled analysis of MTHFR reported results of gene-
environment interaction by folate, alcohol and smoking 
status, showing that MTHFR 677T carriers with a low folate 
status are at particularly increased risk of gastric cancer re-
spect with those carrying the same genotype but with a high-
folate status.  
POLYMORPHISMS IMPACT 
  Overall, by summarizing the results of the published 
meta-analyses of the association between SNPs and gastric 
cancer, a statistically significant increased risk was reported 
for 3 polymorphisms, namely the IL-1B -511T and IL-1RN 
*2 variant allele (carriers status), and MTHFR 677T (homo-
zygous status). A borderline significant increased risk was 
also shown for GSTM1 null variant. Few subgroups meta-
analyses were performed due to absence of published data in 
the primary studies. Among them, however, some demon-
strated a strongly increased risk for gastric cancer among 
those carrying the unfavourable variant of IL- who are con-
temporarily Helicobacter pylori positive [23], those contem-
porarily carrying GSTM1 null and CYP2E1 PstI/RsaI homo-
zygous variant [26], and those contemporarily GSTM1 null 
and GSTT1 null [27,28]. Lastly, the subgroup meta-analysis 
on the pooled report of MTHFR C677T and gastric cancer, A Systematic Review of Meta-Analyses  Current Genomics, 2008, Vol. 9, No. 6    371 
that was published together with a meta-analysis on the same 
research question, demonstrated that the risk of gastric can-
cer among those carrying the homozygous variant genotype 
actually increases only when the folate intake was low [17].  
  The actual impact of polymorphisms on gastric cancer 
risk in the population depends on both the strength of asso-
ciation and on the frequencies of variant alleles, which vary 
among ethnic groups. Calculating PAR for each polymor-
phism among Asians and Caucasians will provide the pro-
portion of gastric cancer cases attributable to the presence of 
the variant genotype, as shown in Table 2. From our compu-
tation, the most impacting polymorphisms are E-cadherin 
-160A and IL-1 -511T (which might account for around 20% 
among Caucasians), MTHFR 677T variant and GSTM1 null 
(both 10% in Asians and Caucasians), IL-1RN *2 and IL-8  
-251A (10% in Caucasians and Asians, respectively). The 
ORs and allele frequencies used for computing the PAR, 
however, are taken from population of different geographic 
areas, although the same ethnic group, which could bias the 
results. As such, further data are needed to obtain a reliable 
estimate of the PAR, including data concerning gene-gene or 
gene-environment interactions, in order to identify popula-
tion subgroups for which the impact of a certain polymor-
phism might be particularly high (e.g., MTHFR 677T variant 
among those with a low dietary intake of folate).  
CONCLUSIONS 
  The integration of genome-based knowledge into health- 
care has the potential to improve primary and secondary pre-
vention [86]. Among the greatest promises of the genomic 
medicine is that the unravelling of the genetic origins of 
common diseases will lead to individualized medicine, in 
which the prevention and treatment strategies are personal-
ized on the basis of the results of predictive genetic tests. 
Findings from meta-analyses of genetic association studies 
have the potential to provide a comprehensive view of the 
impact of genetic risk factors in disease aetiology, especially 




















Fig. (2). Funnel plot of pooled primary studies included in meta-analyses, before (bottom left) and after (bottom right) stratification accord-
ing to the period of publication of the primary studies included in the meta-analysis (The first period of publication is defined as the period including 
primary studies published on the left fifty percentile of the time period spanning from the first paper published on that polymorphism to the last published 
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ity of gene-environment interaction data on gastric cancer, 
however, is currently limited. As such, primary well pow-
ered studies collecting data on environmental related co-
exposures are strongly requested, since this would eventually 
lead to the identification of population subgroups at higher 
risk of gastric cancer because of a concomitant environ-
mental co-exposure. Findings from the meta- and pooled 
analyses on genetic polymorphisms and risk of gastric cancer 
show an increased risk for individuals carrying MTHFR 
677T allele when the folate status was low and IL-1RN *2 
allele when Helicobacter pylori positive. At the moment the 
potential public health impact for both gene tests is limited, 
however, because of the limited amount of data on which 
results are based on. As for MTHFR gene, a proper evalua-
tion of the clinical utility of MTHFR C677T testing for iden-
tifying gastric cancer susceptibility among populations with 
folate deficiency, as well as the introduction of specific fo-
late supplementation (versus no folate supplementation) are 
therefore warranted. Identically, the evaluation of screening 
programs for Helicobacter pylori infection could be targeted 
according to the genetic make up of individuals, but this re-
quire a more extensive evaluation.  
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